Background: Plerixafor, a reversible CXCR4 antagonist, inhibits interactions between leukemic blasts and the bone marrow stromal microenvironment and may enhance chemosensitivity. A phase 1 trial of plerixafor in combination with intensive chemotherapy in children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS) was performed to determine a tolerable and biologically active dose.
Hodgkin lymphoma and multiple myeloma, in combination with granulocyte colony-stimulating factor (G-CSF). 19, 20 Interestingly, in preclinical models of ALL 11, [21] [22] [23] and AML, [24] [25] [26] plerixafor disrupts leukemia-stroma interactions, mobilizes leukemia cells from the bone marrow, and enhances sensitivity to antileukemic therapies.
Initial trials of plerixafor as a chemosensitizing agent in adults with
relapsed/refractory 27 and newly diagnosed AML 28 demonstrated both safety and efficacy. This strategy has not been tested in the pediatric population. We report the results of a Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) phase 1 trial of plerixafor in combination with chemotherapy in children and young adults with relapsed/refractory acute leukemias and MDS (NCT01319864).
METHODS

Patient eligibility
Eligible patients had relapsed (first or greater relapse) or refractory AML, ALL, secondary AML/MDS, or acute leukemia of ambiguous lineage and were between the ages of 3 and 30 years at the time of study entry. Patients with AML/MDS or leukemia with ambiguous lineage were required to have more than 5% blasts in the bone marrow, while those with ALL were required to have more than 25% blasts in the bone marrow. Prior to entering this study, patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy. At the time of study entry, eligible patients could not have received myelosuppressive therapy or long-acting myeloid growth factor within 14 days or biologic therapy or short-acting myeloid growth factor within 7 days. At least 90 days must have elapsed since hematopoietic stem cell transplant (HSCT) and patients must not have had evidence of active graft-versus-host disease (GVHD) requiring immunosuppressive medications. Other eligibility criteria included Karnofsky/Lansky scores higher than 50%, serum creatinine lower than or equal to the upper limit of normal (ULN) for age or calculated creatinine clearance/radioisotope glomerular filtration rate (GFR) 70 ml/min/1.73 m 2 or more, total bilirubin less than 1.5× ULN for age or normal conjugated bilirubin for age, alanine transaminase (ALT) less than 5× ULN unless due to leukemic involvement, and shortening fraction 27% or more by echocardiogram or ejection fraction 50% or more by gated radionuclide study.
Exclusion criteria included absolute blast count more than 50,000 per l despite cytoreduction with hydroxyurea or leukapheresis, presence of leukemic blasts in the central nervous system (CNS2 or CNS3), uncontrolled active systemic infection, and/or a second cancer other than secondary AML. Pretreatment with intrathecal chemotherapy was allowed to achieve CNS1 status.
The protocol was approved by the institutional review boards/ institutional ethics committees of participating institutions. Written informed consent was obtained from all patients or their legal guardians and age-appropriate assent was obtained according to the guidelines of each participating institution.
Drug administration and study design
The primary objective of this phase 1 trial was to determine the safety and tolerability of plerixafor in combination with re-induction chemotherapy in pediatric and young adult patients with relapsed or refractory acute leukemias and MDS. Secondary objectives were to (1) estimate the response rate, (2) determine the pharmacokinetics (PK) of plerixafor in this treatment regimen and patient population, (3) quantify mobilization of leukemic blasts into the peripheral blood, (4) measure the quantitative expression of CXCR4 on leukemic blasts at baseline, and (5) evaluate changes in quantitative expression of CXCR4 on residual leukemic blasts after cycle 1. This phase 1 dose-escalation study utilized the rolling six-trial design, 29 which allowed between two and six patients to be enrolled concurrently onto a given dose level.
The starting dose of plerixafor was 6 mg/m 2 /dose (dose level 1, DL1), which was approximately 80% of the dose tested in the phase 2 adult AML trial. 27 Dose levels for subsequent groups of patients included 9 mg/m 2 /dose (DL2), 12 mg/m 2 /dose (DL3), and 15 mg/m 2 /dose (DL4). Dose escalation was based on a prior study of the safety and mobilization of CD34+ cells using escalating doses of plerixafor, which demonstrated a trend toward higher peak CD34+ counts at doses up to 0.48 mg/kg (roughly equivalent to 15 mg/m 2 ) in healthy adult volunteers. 30 In case of dose-limiting toxicity (DLT), the study allowed for one dose de-escalation level (DL1, 3 mg/m 2 /dose).
On day 1, patients received standard age-based doses of intrathecal methotrexate (ALL patients) or cytarabine (AML, MDS, and leukemia with ambiguous lineage patients). On days 1 through 5, plerixafor was administered intravenously (IV) once daily over 30 min followed 4 hr later by high-dose cytarabine (1 g/m 2 IV every 12 hr) over 1 hr and etoposide (150 mg/m 2 IV daily) over 1 hr. The timing of plerixafor prior to chemotherapy administration was the same as that studied in the phase 2 adult AML chemosensitization trial and was based on preclinical and clinical data suggesting that this timing would maximize the interruption of leukemia-stroma interactions. 27 Toxicity was graded during cycle 1 using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
DLT was defined as any grade 3 or higher nonhematologic toxicity that persisted for more than 48 hr without resolution to lower than or equal to grade 2 and was possibly, probably, or definitely attributable to plerixafor, excluding alopecia; anorexia; grade 3 vomiting or diarrhea that resolved to lower than or equal to grade 2 within 48 hr; grade 3 nausea that resolved to lower than or equal to grade 2 within 7 days; asymptomatic grade 3 elevation in amylase, lipase, or total bilirubin that returned to lower than or equal to grade 2 within 7 days; lower than or equal to grade 3 elevation in hepatic transaminases or alkaline phosphatase that returned to lower than or equal to grade 2 within 14 days; grade 3 fever with neutropenia; and grade 3 infection. Failure to recover a peripheral absolute neutrophil count higher than 500 per l or a nontransfusion-dependent platelet count higher than 20,000 per l by day 56, without the evidence of residual leukemia, was also considered a DLT. Attribution of toxicities to the study drug were determined by treating physicians. Patients evaluable for DLT were defined as those who (1) experienced DLT after receiving at least one dose of plerixafor or (2) did not experience DLT and received 80% or more of planned doses of plerixafor.
Response was assessed via bone marrow aspiration performed at the end of cycle 1 (upon count recovery but no later than day 28).
Patients who achieved a response of stable disease or better were eligible to receive a second cycle of therapy, as long as all grade 3 or higher toxicities had resolved to baseline or lower than grade 2. DLT was assessed in the first cycle only. Patients evaluable for response were defined as those who (1) met the definition of progressive disease after receiving at least one dose of plerixafor or (2) did not meet the definition of progressive disease, received at least 80% of the planned doses of plerixafor and had the required response evaluation performed at the end of the first course of therapy.
PK studies
Peripheral blood (2 ml) for PK studies was collected at hour 0 (immediately prior to the plerixafor infusion), within 5 min prior to the end of the plerixafor infusion, and hours 1, 2, 4, 8, and 24 on days 1 and 5 of cycle 1. Blood for PK studies was collected from a site separate from the line used for plerixafor infusion. Plasma was then separated by centrifugation at 3,000 × g for 10 min, divided into two equal aliquots, stored at -80°C, and analyzed in batches. Plerixafor plasma concentrations were measured using a validated liquid chromatography-mass spectrometry-mass spectrometry analytical method.
Plasma PK parameters were estimated by noncompartmental analysis using Phoenix WinNonlin 7.0 (Certara). Maximum plasma concentration (C max ), area under the concentration-time curve from time 0 to 24 hr (AUC 0-24h ), terminal half-life (t 1/2 ), and systemic clearance were estimated from the observed concentration-time data.
Correlative biology studies
To measure CXCR4 expression, bone marrow aspirates were obtained at study entry (baseline) and after cycle 1. Peripheral blood mononuclear cells were isolated via Ficoll density centrifugation as previously described. 22 Cells were then prepared for flow cytometry analysis as previously described. 23 Briefly, cells were stained with antibodies against human CD45, CD34, CD19, CD33, CXCR4 (12G5, eBioscience, San Diego, CA), and isotype controls and were read on a FACSCalibur (all from BD Biosciences, San Diego, CA, except as noted). Analysis to identify leukemic blasts was performed using FlowJo software for flow cytometry (FlowJo, LLC, Ashland, OR) and surface CXCR4 expression in the blast population was quantified as mean fluorescence intensity (MFI) relative to isotype control.
To measure peripheral blood mobilization of leukemic blasts, paired aliquots of whole blood (4 ml) were collected from each patient immediately before the first dose of plerixafor (hour 0) and at hour 4. After red blood cell lysis, cells were counted using a hemacytometer and Trypan Blue exclusion. Flow cytometry was then performed as described above to identify leukemic blasts. Absolute peripheral blood leukemic blast counts were calculated by multiplying the percentage of leukemic blasts by the total cell count.
Student's t-tests were used to calculate P values. Alpha was set to 0.05. Correlation between CXCR4 expression and leukemic blast mobilization was assessed by Pearson correlation coefficient.
RESULTS
Patient characteristics
Twenty patients were enrolled between July 2011 and June 2013. One patient consented to the trial but did not initiate protocol therapy. One patient received less than 80% of planned plerixafor doses and was removed from protocol therapy for reasons other than DLT or progressive disease, and thus was not evaluable for DLT or response. This patient had preexisting abdominal pain that worsened significantly after the first day of protocol therapy. Specifically, after receiving the first day of protocol therapy consisting of plerixafor (12 mg/m 2 ), etoposide, and cytarabine, there was radiographic evidence of neutropenic colitis and treatment was discontinued. Given antecedent prolonged leukemia with cytopenias and the timing of clinical findings, the investigator determined this was not related to plerixafor but not in the patient's best interest to continue intensive protocol therapy. Therefore, 18 patients were evaluable for DLT and response; the characteristics of these 18 patients are summarized in Table 1 . All patients with ALL had B-lineage ALL. Of note, one third of patients (n = 6) were in second or greater relapse. Specifically, the median number of prior treatment regimens was 2.5 (range 2-5) for patients with ALL and 2 (range 1-5) for patients with AML. Nearly half (n = 8) of the evaluable patients had previously undergone HSCT.
Toxicity
Nineteen patients (including the inevaluable patient mentioned above) received at least one dose of study drug. Patients were treated at all four planned dose levels of plerixafor (three patients at DL1, five at DL2, five at DL3, and six at DL4). Plerixafor dose de-escalation was not necessary. There were no DLTs or delays in count recovery attributable to plerixafor. In general, toxicities were consistent with intensive relapsed leukemia regimens. The most common grade 1 and 2 toxicities attributed to plerixafor occurring in more than 20% of the patients included nausea (n = 12); anorexia (n = 11); vomiting (n = 9); diarrhea and hypocalcemia (n = 8 each); headache and hypoalbuminemia (n = 7 each); abdominal pain (n = 6); increased ALT (n = 5); and constipation, fatigue, hyperglycemia, hypertriglyceridemia, and hypokalemia (n = 4 each). The most common grade 3 or greater nonhematologic toxicities attributed to plerixafor that occurred in more than 10% of the patients included febrile neutropenia (n = 4), hypokalemia (n = 3), anorexia, Several patients had multiple molecular abnormalities. All patients with ALL had B-lineage ALL.
hyperglycemia, hypotension, mucositis, typhlitis, and vomiting (n = 2 each) ( Table 2 ).
Response
As shown in Table 3 , two patients achieved complete remission (CR) (<5% bone marrow blasts and no evidence of circulating blasts or extramedullary disease, ANC >1,000 per l, and platelet count >100,000 per l) and one patient achieved CR with incomplete hematologic recovery (Cri) (CR without recovery of ANC or platelet count to aforementioned levels). Notably, all three of these responses were in patients with AML. The two patients who achieved CR were treated at DL1 and DL3, while the one patient who achieved CRi was treated at TA B L E 2 Grade 2 and higher toxicities possibly or probably related to plerixafor (n = 19 patients) 
Pharmacokinetics
Plerixafor PK parameters on days 1 and 5 are summarized in Table 4 . 
Correlative biology studies
Adequate bone marrow aspirates for baseline correlative biology stud- 
DISCUSSION
Plerixafor in combination with an intense chemotherapeutic regimen was well tolerated in children and young adults with relapsed/refractory acute leukemias and MDS. Observed adverse events were largely consistent with toxicity profiles from conventional chemotherapy regimens for pediatric acute leukemias. Because CXCR4 is expressed on the surface of HSCs and white blood cells, an important finding was that the addition of plerixafor to high-dose cytarabine and etoposide did not lead to delayed count recovery in the patients studied. In initial adult AML chemosensitization trials, the addition of plerixafor to chemotherapy also did not result in delayed count recovery. 27, 28 Compared with PK assessments in adult volunteers receiving intravenous plerixafor, 31 PK analysis in this study revealed a similar half-life but decreased clearance of plerixafor. Drug clearance did not differ between days 1 and 5, implying that there was no accumulation of plerixafor over the period studied.
As reported in other trials of plerixafor in children and adults with acute leukemias, 27, 28, 32 we observed that plerixafor mobilized leukemic blasts into the peripheral blood. Despite heterogeneous expression of surface CXCR4, mobilization occurred in the vast majority of patients in this trial. In addition, higher CXCR4 expression correlated with higher blast mobilization. Thus, it is possible that surface CXCR4 expression may predict responsiveness to plerixafor. For example, in vitro studies in ALL and AML cell lines found that chemotherapyinduced increases in surface CXCR4 expression were positively associated with the degree of chemosensitization by plerixafor. 23, 26 In this trial, we hoped to explore this finding further; but, due to low patient numbers and limited responses, we could not correlate changes in surface CXCR4 expression with response in a statistically meaningful way.
Surface CXCR4 expression, as measured by the 12G5 antibody, increased after plerixafor treatment (Fig. 1D) . The 12G5 CXCR4 antibody is specific for the site at which both CXCL12 and plerixafor bind. Previous work suggested that continuous exposure to plerixafor in vitro for 72 hr leads to increased surface expression of CXCR4. 23 In adults with AML, plerixafor also increased surface CXCR4 expression. 27, 33 Higher levels of surface CXCR4 expression in residual leukemic blasts may lead to untoward consequences, including increased responsiveness to CXCL12, resulting in decreased sensitivity to chemotherapy. 23 We observed three complete responses (two CR, one CRi) in this heavily pretreated population of children with relapsed/refractory ALL, AML, and MDS. However, the design of this study does not allow us to conclude that plerixafor was responsible for the CRs.
We were intrigued that all observed responses were in patients with AML. However, with the sample size of only 12 patients, the point estimate of 25% for CR/CRi in AML patients has a 95% confidence interval ranging from 0.5-49.5%. Similarly, the lack of response seen in patients with ALL and MDS is difficult to interpret given the sample sizes of five and one patients, respectively. While the overall response rate on this study was modest, the study was not designed or powered to definitively address an efficacy question. Whether further study of this regimen is warranted will depend upon the relative enthusiasm for this approach compared with other novel approaches available for this patient population. With a CR+CRi rate of 25% (range 0.5-49.5%) in pediatric patients with heavily pretreated relapsed AML, and no evidence of enhanced toxicity, this regimen is not an unreasonable candidate for further study.
It is also important to recognize that clinical trials of CXCR4 chemosensitization in acute leukemias, including this one, have focused on AML and B-lineage ALL. Recently, the potential importance of CXCR4 and CXCL12 in T-cell ALL (T-ALL) was demonstrated in two elegant studies. 38, 39 Silencing of CXCR4 by small hairpin RNA decreased leukemia engraftment and leukemia-initiating capacity in transplant models of murine and human T-ALL. 39 Further, administration of the CXCR4 inhibitor AMD3465 as a single agent significantly decreased leukemic burden in murine T-ALL and xenografts of primary T-ALL samples. 38 Therefore, CXCR4 inhibition may be a potential therapeutic approach in T-ALL. Because our trial did not enroll any T-ALL patients, further studies will be required to address this question.
It is possible that response rates could be improved by optimizing the treatment backbone with additional chemotherapeutic agents or targeted therapies, or by adding G-CSF, which has been shown to decrease CXCL12 production by stromal cells. 40 Remarkably, plerixafor and G-CSF have been shown to augment the effectiveness of targeted therapies in high-risk leukemias in preclinical models 22 and in clinical trials. 33 For example, plerixafor and G-CSF greatly enhanced the efficacy of the FLT3 tyrosine kinase inhibitor lestaurtinib in a xenograft model of infant MLL-rearranged ALL. 22 Also, a phase 1 trial of plerixafor, G-CSF, and sorafenib in adults with relapsed/refractory FLT3-ITD+AML reported a CR+CRi rate of 31% in this very difficult to treat population, as well as a 41-fold increase in circulating blasts after mobilization. 33 Therefore, while the study reported here was associated with modest responses, targeting leukemia-stroma interactions through CXCR4 inhibition may yet prove to be an effective strategy in the treatment of high-risk leukemias.
We conclude that CXCR4 inhibition as a chemosensitization strategy is safe in children and young adults with relapsed/refractory acute leukemias and MDS. These findings support the consideration for the continued clinical development of bone marrow microenvironmenttargeted agents in pediatric acute leukemias. 
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